Content Type: Commentary & Opinion

The Regulatory Accountability Act of 2017—Implications for FDA Regulation and Public Health

March 16, 2026

The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire Upon Generic Entry?

March 16, 2026

Role of Authorized Generics in Postapproval Surveillance of Generic Drug Products

March 16, 2026

Accelerating Innovation in Rapid Diagnostics and Targeted Antibacterials

March 16, 2026

Use the Bayh-Dole Act to Lower Drug Prices for Government Healthcare Programs

March 16, 2026

Up Is Down—Pharmaceutical Industry Caution vs. Federal Acceleration of COVID-19 Vaccine Approval

March 16, 2026

The Evidence Landscape in Precision Medicine

March 16, 2026

FDA Approval Standards for Anticancer Agents—Lessons From Two Recent Approvals in Breast Cancer

March 16, 2026

Government Patent Use to Address the Rising Cost of Naloxone: 28 U.S.C. § 1498 and Evzio

March 16, 2026

Integrating New Effectiveness Data Into US Food and Drug Administration-Approved Drug Labeling

March 16, 2026

Questions About the 10 X ’20 Initiative

March 16, 2026

Three Design Aspects for High Quality Post-Marketing Cohort Studies

March 16, 2026